tNTI-SCATTER GRIDS AND COLLIMATOR DESIGNS, AND THEIR MOTION, FABRICATION AND ASSEMBLY
    41.
    发明申请
    tNTI-SCATTER GRIDS AND COLLIMATOR DESIGNS, AND THEIR MOTION, FABRICATION AND ASSEMBLY 审中-公开
    tNTI散热器网格和收集器设计及其运动,制造和组装

    公开(公告)号:WO02065480A8

    公开(公告)日:2003-11-06

    申请号:PCT/US0202711

    申请日:2002-02-01

    CPC classification number: G21K1/025

    Abstract: Grids (30) and collimators, for use with electromagnetic energy emitting devices (61), include at least a metal layer that is formed, for example, by electroplating/electroforming or casting. The metal layer includes top and bottom surfaces, and a plurality of solid integrated walls (32). Each of the solid integrated walls extends from the top to bottom surface and has a plurality of side surfaces. The side surfaces of the solid integrated walls are arranged to define a plurality of openings (31) extending entirely through the layer. At least some of the walls (32) also can include projections extending into the respective openings formed by the walls (32). The projections can be of various shapes and sizes, and are arranged so that a total amount of wall material intersected by a line propagating in a direction along an edge of the grid (30) is substantially the same as another total amount of wall material intersected by another line propagating in another direction substantially parallel to the edge of the grid (30) at any distance from the edge. Methods to fabricate these grids (30) using copper, lead, nickel, gold, any other electroplating/electroforming materials or low melting temperature metals are described.

    Abstract translation: 与电磁能发射装置(61)一起使用的格栅(30)和准直器至少包括通过例如电镀/电铸或铸造形成的金属层。 金属层包括顶表面和底表面,以及多个固体一体化壁(32)。 每个固体一体化壁从顶部到底部表面延伸并且具有多个侧表面。 固体一体化壁的侧表面布置成限定完全延伸穿过该层的多个开口(31)。 至少一些壁(32)还可以包括延伸到由壁(32)形成的相应开口中的突起。 突起可以是各种形状和尺寸,并且被布置成使得沿着沿着格栅(30)的边缘的方向传播的线相交的壁材料的总量基本上与另外的总量的壁材料相交 通过在与边缘任何距离处基本上平行于栅格(30)的边缘的另一方向上传播的另一条线。 描述了使用铜,铅,镍,金,任何其它电镀/电铸材料或低熔点金属制造这些栅极(30)的方法。

    Use of circulating tumor cell mitotic index in cancer stratification and diagnostics

    公开(公告)号:US11150245B2

    公开(公告)日:2021-10-19

    申请号:US15576472

    申请日:2016-05-26

    Abstract: Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

    Uso del índice mitótico de células tumorales circulantes en la estratificación y diagnóstico de cáncer

    公开(公告)号:ES2765981T3

    公开(公告)日:2020-06-11

    申请号:ES16731403

    申请日:2016-05-26

    Abstract: Un procedimiento para predecir la probabilidad de supervivencia de un sujeto que tiene cáncer, en el que el procedimiento comprende: (a) obtener una población de CTC de una muestra biológica de un sujeto que tiene cáncer, en el que preferentemente la muestra biológica se selecciona del grupo que consiste en sangre periférica, sangre, ganglios linfáticos, médula ósea, líquido cefalorraquídeo y orina, en el que incluso más preferentemente, la muestra biológica es al menos aproximadamente 7,5 ml de sangre periférica, y (b) cribar la población de CTC en busca de células en una fase del ciclo celular mitótico, en el que cuando se identifica una o más CTC por estar en una fase del ciclo celular mitótico, se predice que el sujeto tiene una menor probabilidad de supervivencia en comparación con un sujeto que tiene el mismo cáncer que no tiene una o más CTC identificadas por estar en una fase del ciclo celular mitótico, por lo que predice la probabilidad de supervivencia de un sujeto que tiene cáncer, preferentemente en el que la fase del ciclo celular mitótico se determina tiñendo las células con una tinción nuclear y determinar visualmente la fase del ciclo celular.

    Polymer microfiltration devices, methods of manufacturing the same and the uses of the microfiltration devices

    公开(公告)号:AU2017268660A1

    公开(公告)日:2017-12-21

    申请号:AU2017268660

    申请日:2017-12-01

    Abstract: A microfilter comprising a polymer layer formed from epoxy-based photo-definable dry film, and a plurality of apertures each extending through the polymer layer. A microfilter comprising two or more polymer layers formed from epoxy-based photo-definable dry film, and a plurality of apertures or open areas each extending through the polymer layer. A method of forming a microfilter is also disclosed. The method includes providing a first layer of epoxy-based photo definable dry film disposed on a substrate, exposing the first layer to energy through a mask to form a pattern, defined by the mask, in the first layer of dry film, forming, from the exposed first layer of dry film, a polymer layer having a plurality of apertures extending therethrough, the plurality of apertures having a distribution defined by the pattern, and removing the polymer layer from the substrate. Unique filter holder designs and methods appropriate to hold microfilters to collect the rare cells and allow performing assays in the filter holder are provided. The invention also describes the use of the microfilter and filter holder to collect rare cells from body fluids and perform assays. Rare cells collected on the microfilter in accordance with embodiments of the present invention can be used for medical and biological research applications.

    METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY

    公开(公告)号:CA3020854A1

    公开(公告)日:2017-10-19

    申请号:CA3020854

    申请日:2017-04-14

    Abstract: Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.

Patent Agency Ranking